Pfizer’s Sigvotatug Vedotin Fails Phase III NSCLC Trial, Shares Drop 1.5%
PFE•Pfizer’s experimental lung cancer drug sigvotatug vedotin failed to extend overall survival versus docetaxel in metastatic non-squamous NSCLC, causing shares to fall about 1.5%. The setback follows Pfizer’s $43 billion Seagen acquisition and shifts focus to ongoing combination trials with Keytruda in first-line treatment.
1. Phase III Trial Failure
Pfizer’s antibody–drug conjugate sigvotatug vedotin did not significantly improve overall survival compared with docetaxel in patients with previously treated metastatic non-squamous NSCLC, failing the primary endpoint of the study.
2. Market Reaction and Acquisition Context
Shares of Pfizer fell roughly 1.5% in late trading following the trial results, underscoring investor concern after Pfizer spent $43 billion to acquire Seagen’s oncology assets, including sigvotatug vedotin.
3. Ongoing Combination Studies
Pfizer is proceeding with a separate late-stage trial evaluating sigvotatug vedotin plus Keytruda as a first-line therapy for newly diagnosed non-squamous NSCLC patients, based on earlier data suggesting improved efficacy in combination settings.
